TY - JOUR
T1 - The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA)
AU - Ta, Andrew
AU - Kaur, Supreet
AU - Mader, Michael
AU - Franklin, Kathleen
AU - Williams, Madison
AU - Williams, Ryan
AU - Blaize, Jean Pierre
AU - Naqvi, Amna
AU - Ananth, Snegha
AU - Song, Michael
AU - Warnecke, Brian Oliver
AU - Pandya, Abhishek
AU - Djoumessi, Lakene Raissa Djoufack
AU - Nazarewicz, Phillip
AU - Espinoza-Gutarra, Manuel
AU - Lucero, Kana Tai
AU - Whitehead, Jennifer
AU - Al-Abayechi, Alaq
AU - Boyle, Lauren
AU - Lee, Sophia
AU - Roman Souza, Gabriel
AU - Toro Velez, Esteban
AU - Mines, Ian
AU - Nooruddin, Zohra
N1 - Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly male (97%) and white (75%). Median age of diagnosis for Black patients was 63 years vs 69 years for the entire cohort (p < 0.001). However, patients in each race/ethnicity subgroup presented with similar rates of stage I/II and III/IV disease, IPI score, cell of origin and HIT status. Outcomes analysis revealed similar treatment, response rates, median overall survival, and 1-, 3-, and 5-year survival across all subgroups. Hispanic patients had a 21% lower risk of death (HR = 0.79) than white patients, and Black patients had no significant difference in survival (HR = 0.98). This large retrospective study shows that when standard of care therapy is given within an equal access system, short-term treatment and survival outcomes are the same for all races.
AB - We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly male (97%) and white (75%). Median age of diagnosis for Black patients was 63 years vs 69 years for the entire cohort (p < 0.001). However, patients in each race/ethnicity subgroup presented with similar rates of stage I/II and III/IV disease, IPI score, cell of origin and HIT status. Outcomes analysis revealed similar treatment, response rates, median overall survival, and 1-, 3-, and 5-year survival across all subgroups. Hispanic patients had a 21% lower risk of death (HR = 0.79) than white patients, and Black patients had no significant difference in survival (HR = 0.98). This large retrospective study shows that when standard of care therapy is given within an equal access system, short-term treatment and survival outcomes are the same for all races.
KW - African Americans
KW - Hispanics
KW - Lymphoma and Hodgkin disease
KW - diffuse large B-cell lymphoma
KW - disparities
KW - health disparities
UR - https://www.scopus.com/pages/publications/85191002689
UR - https://www.scopus.com/pages/publications/85191002689#tab=citedBy
U2 - 10.1080/10428194.2024.2338856
DO - 10.1080/10428194.2024.2338856
M3 - Article
C2 - 38619488
AN - SCOPUS:85191002689
SN - 1042-8194
VL - 65
SP - 1090
EP - 1099
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 8
ER -